Click is also working on DTx candidates for schizophrenia with Boehringer Ingelheim and with Indivior on software to support people with substance use disorders. Its in-house pipeline is led by a ...
German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...